Fauquier ENT is 1 of 13 Sites Nationally to Participate in a New Research Study

There is a new study beginning the spring/summer of 2007 in Warrenton, VA to address the excessive dry mouth patients experience after undergoing radiation treatment for head & neck cancer. The primary objective is to assess the impact of the drug Evoxac (cevimeline) on salivary flow at a dose of 30mg three times daily. Of note, this drug and dosage has already been approved by the FDA for treatment of dry mouth in patients with Sjogren's syndrome, an autoimmune disease that causes dry mouth.

Fauquier ENT is one of only 13 sites nationally participating in this study which is coordinated by the Duke Clinical Research Institute and the American Academy of Otolaryngology-Head & Neck Surgery.

Contact our office if you would like to participate in this study. This study is anticipated to be completed end of 2008.